| アブストラクト | INTRODUCTION: Anticancer drug-induced stomatitis can affect a patient's quality of life and the continuation of drug treatment. Although there have been reports of the occurrence of stomatitis associated with anticancer agents in clinical trials, few Japanese participants have been enrolled in clinical trials and have not been sufficiently investigated. In addition, there has been little attention on research on anticancer drugs associated with stomatitis by patient stratification with different carcinogenic sites. Therefore, the aim of this study was to determine the disproportionality associated with stomatitis for various types of anticancer drugs in different types of cancer patients using the Japanese Adverse Drug Event Report (JADER) database. METHODS: The aim of this study was to identify the disproportionality of stomatitis by analyzing the type of anticancer drug and cancer patients using the Japanese Pharmacovigilance Database. Data obtained from spontaneous reports of adverse events with more than 10 stomatitis outbreaks reported in the JADER database between April 2004 and March 2023 were analyzed. The safety signal for an adverse event was defined as the lower limit of the 95% confidence interval of the reported odds ratio of >1. RESULTS: There were 6,178 reports of drugs associated with stomatitis. Among these, 41 drugs were suggested to be associated with stomatitis, and 41 drugs were detected as signals. These drugs were classified based on their efficacy: antipyrimidines (six drugs), folate metabolism antagonists (three drugs), alkylating agents (four drugs), platinum (three drugs), topoisomerase inhibitors (three drugs), microtubule inhibitors (three drugs), mammalian target of rapamycin (mTOR) inhibitors (two drugs), kinase inhibitors (seven drugs), anti-growth factor antibodies (five drugs) immune checkpoint inhibitors (one drug), and others (four drugs). CONCLUSION: The drugs that may be associated with stomatitis were cell cycle-dependent drugs, epidermal growth factor receptor-tyrosine kinase inhibitors, and mTOR inhibitors. Moreover, this study suggested that anti-growth factor antibodies and immune checkpoint inhibitors may be associated with stomatitis development. |
|---|
| ジャーナル名 | Oncology |
|---|
| 投稿日 | 2024/1/11 |
|---|
| 投稿者 | Hosonaka, Kousuke; Yamaoka, Kenta; Ikeda, Naoe; Uchida, Mayako; Uesawa, Yoshihiro; Takahashi, Kazushige; Shimizu, Tadashi |
|---|
| 組織名 | School of Pharmacy, Hyogo Medical University, Kobe, Japan.;Department of Pharmacy, Osaka-fu Saiseikai Noe Hospital, Osaka, Japan.;Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Japan.;Department of Education and Research Center for Pharmacy Practice, Faculty of;Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe,;Japan.;Department of Medical Molecular Informatics, Meiji Pharmaceutical University,;Kiyose, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38198784/ |
|---|
